van der Feltz, C, Anthony, K, Brilot, A, Pomeranz Krummel, DA. Architecture of the spliceosome. Biochemistry 2012, 51:3321–3333.
Kornblihtt, AR, Schor, IE, Alló, M, Dujardin, G, Petrillo, E, Muñoz, MJ. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol 2013, 14:153–165.
Barash, Y, Calarco, JA, Gao, W, Pan, Q, Wang, X, Shai, O, Blencowe, BJ, Frey, BJ. Deciphering the splicing code. Nature 2010, 465:53–59.
Treutlein, B, Gokce, O, Quake, SR, Südhof, TC. Cartography of neurexin alternative splicing mapped by single‐molecule long‐read mRNA sequencing. Proc Natl Acad Sci 2014, 111:E1291–E1299.
Xu, D, Liu, W, Alvarez, A, Huang, T. Cellular immune responses against viral pathogens in shrimp. Dev Comp Immunol 2014, 47:287–297.
Colak, R, Kim, T, Michaut, M, Sun, M, Irimia, M, Bellay, J, Myers, CL, Blencowe, BJ, Kim, PM. Distinct types of disorder in the human proteome: functional implications for alternative splicing. PLoS Comput Biol 2013, 9:e1003030.
Kanemori, Y, Ryu, JH, Sudo, M, Niida‐Araida, Y, Kodaira, K, Takenaka, M, Kohno, N, Sugiura, S, Kashiwabara, S, Baba, T. Two functional forms of ACRBP/sp32 are produced by pre‐mRNA alternative splicing in the mouse. Biol Reprod 2013, 88:1–8.
McManus, CJ, Coolon, JD, Eipper‐Mains, J, Wittkopp, PJ, Graveley, BR. Evolution of splicing regulatory networks in Drosophila. Genome Res 2014, 24:786–796.
Kuroyanagi, H, Takei, S, Suzuki, Y. Comprehensive analysis of mutually exclusive alternative splicing in C. elegans. Worm 2014, 31:e28459.
Pedrotti, S, Cooper, TA. In Brief: (mis)splicing in disease. J Pathol 2014, 233:1–3.
Tazi, J, Bakkour, N, Stamm, S. Alternative splicing and disease. Biochim Biophys Acta 2009, 1792:14–26.
Popp, MW, Maquat, LE. Organizing principles of mammalian nonsense‐mediated mRNA decay. Annu Rev Genet 2013, 47:139–165.
Kalyna, M, Simpson, CG, Syed, NH, Lewandowska, D, Marquez, Y, Kusenda, B, Marshall, J, Fuller, J, Cardle, L, McNicol, J, et al. Alternative splicing and nonsense‐mediated decay modulate expression of important regulatory genes in Arabidopsis. Nucleic Acids Res 2012, 40:2454–2469.
Miura, K, Fujibuchi, W, Unno, M. Splice variants in apoptotic pathway. Exp Oncol 2012, 34:212–217.
Liu, S, Cheng, C. Alternative RNA splicing and cancer. WIREs RNA 2013, 4:547–566.
Fan, X, Tang, L. Aberrant and alternative splicing in skeletal system disease. Gene 2013, 528:21–26.
Feng, D, Xie, J. Aberrant splicing in neurological diseases. WIREs RNA 2013, 4:631–649.
Kelemen, O, Convertini, P, Zhang, Z, Wen, Y, Shen, M, Falaleeva, M, Stamm, S. Function of alternative splicing. Gene 2013, 514:1–30.
Venables, JP, Klinck, R, Koh, C, Gervais‐Bird, J, Bramard, A, Inkel, L, Durand, M, Couture, S, Froehlich, U, Lapointe, E, et al. Cancer‐associated regulation of alternative splicing. Nat Struct Mol Biol 2009, 16:670–676.
Michels, J, Kepp, O, Senovilla, L, Lissa, D, Castedo, M, Kroemer, G, Galluzzi, L. Functions of BCL‐XL at the interface between cell death and metabolism. Int J Cell Biol 2013, 2013:705294.
Cho, HJ, Kim, JK, Kim, KD, Yoon, HK, Cho, MY, Park, YP, Jeon, JH, Lee, ES, Byun, SS, Lim, HM, et al. Upregulation of Bcl‐2 is associated with cisplatin‐resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 2006, 237:56–66.
DeOcesano‐Pereira, C, Amaral, MS, Parreira, KS, Ayupe, AC, Jacysyn, JF, Amarante‐Mendes, GP, Reis, EM, Verjovski‐Almeida, S. Long non‐coding RNA INXS is a critical mediator of BCL‐XS induced apoptosis. Nucleic Acids Res 2014, 42:8343–8355.
Chang, JG, Yang, DM, Chang, WH, Chow, LP, Chan, WL, Lin, HH, Huang, HD, Chang, YS, Hung, CH, Yang, WK. Small molecule amiloride modulates oncogenic RNA alternative splicing to devitalize human cancer cells. PLoS One 2011, 6:e18643.
Shkreta, L, Froehlich, U, Paquet, ER, Toutant, J, Elela, SA, Chabot, B. Anticancer drugs affect the alternative splicing of Bcl‐x and other human apoptotic genes. Mol Cancer Ther 2008, 7:1398–1409.
Xiao, Y, Xiong, H, Li, J, Liu, J, Zhang, H, Huang, B, Wang, C, Longhua, H, Wang, X. Imatinib regulates the alternative pre‐mRNA splicing of Bcl‐x in K562 cells. Asian Biomed 2012, 6:351–359.
Pilch, B, Allemand, E, Facompré, M, Bailly, C, Riou, JF, Soret, J, Tazi, J. Specific inhibition of serine and arginine‐rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB‐506. Cancer Res 2001, 61:6876–6884.
Rohrbach, S, Muller‐Werdan, U, Werdan, K, Koch, S, Gellerich, NF, Holtz, J. Apoptosis‐modulating interaction of the neuregulin/erbB pathway with anthracyclines in regulating Bcl‐xS and Bcl‐xL in cardiomyocytes. J Mol Cell Cardiol 2005, 38:485–493.
Chang, WH, Liu, TC, Yang, WK, Lee, CC, Lin, YH, Chen, TY, Chang, JG. Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr‐AblT315I mutant cells to imatinib. Cancer Res 2011, 71:383–392.
Ling, Q, Xu, X, Wei, X, Wang, W, Zhou, B, Wang, B, Zheng, S. Oxymatrine induces human pancreatic cancer PANC‐1 cells apoptosis via regulating expression of Bcl‐2 and IAP families, and releasing of cytochrome c. J Exp Clin Cancer Res 2011, 30:66.
Chalfant, CE, Rathman, K, Pinkerman, RL, Wood, RE, Obeid, LM, Ogretmen, B, Hannun, YA. De novo ceramide regulates the alternative splicing of caspase‐9 and Bcl‐x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase‐1. J Biol Chem 2002, 277:12587–12595.
Boon‐Unge, K, Yu, Q, Zou, T, Zhou, A, Govitrapong, P, Zhou, J. Emetine regulates the alternative splicing of Bcl‐x through a protein phosphatase 1‐dependent mechanism. Chem Biol 2007, 14:1386–1392.
Sharma, R, Callaway, D, Vanegas, D, Bendele, M, Lopez‐Cruzan, M, Horn, D, Guda, T, Fajardo, R, Abboud‐Werner, S, Herman, B. Caspase‐2 maintains bone homeostasis by inducing apoptosis of oxidatively‐damaged osteoclasts. PLoS One 2014, 9:e93696.
Cao, X, Bennett, RL, May, WS. c‐Myc and caspase‐2 are involved in activating Bax during cytotoxic drug‐induced apoptosis. J Biol Chem 2008, 283:14490–14496.
Delgado, ME, Olsson, M, Lincoln, FA, Zhivotovsky, B, Rehm, M. Determining the contributions of caspase‐2, caspase‐8 and effector caspases to intracellular VDVADase activities during apoptosis initiation and execution. Biochim Biophys Acta 1833, 2013:2279–2292.
Schwerk, C, Schulze‐Osthoff, K. Regulation of apoptosis by alternative pre‐mRNA splicing. Mol Cell 2005, 19:1–13.
Jang, HN, Lee, M, Loh, TJ, Choi, SW, Oh, HK, Moon, H, Cho, S, Hong, SE, Kim do, H, Sheng, Z, et al. Exon 9 skipping of apoptotic caspase‐2 pre‐mRNA is promoted by SRSF3 through interaction with exon 8. Biochim Biophys Acta 2014, 839:25–32.
Han, C, Zhao, R, Kroger, J, Qu, M, Wani, AA, Wang, QE. Caspase‐2 short isoform interacts with membrane‐associated cytoskeleton proteins to inhibit apoptosis. PLoS One 2013, 8:e67033.
Solier, S, Lansiaux, A, Logette, E, Wu, J, Soret, J, Tazi, J, Bailly, C, Desoche, L, Solary, E, Corcos, L. Topoisomerase I and II inhibitors control caspase‐2 pre‐messenger RNA splicing in human cells. Mol Cancer Res 2004, 2:53–61.
Fan, L, Lagisetti, C, Edwards, CC, Webb, TR, Potter, PM. Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol 2011, 6:582–589.
Wotawa, A, Solier, S, Logette, E, Solary, E, Corcos, L. Differential influence of etoposide on two caspase‐2 mRNA isoforms in leukemic cells. Cancer Lett 2002, 185:181–189.
Hu, Q, Wu, D, Chen, W, Yan, Z, Yan, C, He, T, Liang, Q, Shi, Y. Molecular determinants of caspase‐9 activation by the Apaf‐1 apoptosome. Proc Natl Acad Sci 2014, 111:16254–16261.
Würstle, ML, Laussmann, MA, Rehm, M. The central role of initiator caspase‐9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. Exp Cell Res 2012, 318:1213–1220.
Shultz, JC, Goehe, RW, Murudkar, CS, Wijesinghe, DS, Mayton, EK, Massiello, A, Hawkins, AJ, Mukerjee, P, Pinkerman, RL, Park, MA, et al. SRSF1 regulates the alternative splicing of caspase‐9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non‐small cell lung cancer cells. Mol Cancer Res 2011, 9:889–900.
Golan‐Gerstl, R, Cohen, M, Shilo, A, Suh, SS, Bakàcs, A, Coppola, L, Karni, R. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 2011, 71:4464–4472.
Vu, NT, Park, MA, Shultz, JC, Goehe, RW, Hoeferlin, LA, Shultz, MD, Smith, SA, Lynch, KW, Chalfant, CE. hnRNP U enhances caspase‐9 splicing and is modulated by AKT‐dependent phosphorylation of hnRNP L. J Biol Chem 2013, 288:8575–8584.
Goehe, RW, Shultz, JC, Murudkar, C, Usanovic, S, Lamour, NF, Massey, DH, Zhang, L, Camidge, DR, Shay, JW, Minna, JD, et al. hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase‐9 pre‐mRNA processing. J Clin Invest 2010, 120:3923–3939.
Shultz, JC, Goehe, RW, Wijesinghe, DS, Murudkar, C, Hawkins, AJ, Shay, JW, Minna, JD, Chalfant, CE. Alternative splicing of caspase‐9 is modulated by the phosphoinositide 3‐kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res 2010, 70:9185–9196.
Hagen, RM, Chedea, VS, Mintoff, CP, Bowler, E, Morse, HR, Ladomery, MR. Epigallocatechin‐3‐gallate promotes apoptosis and expression of the caspase‐9a splice variant in PC3 prostate cancer cells. Int J Oncol 2013, 43:194–200.
Patwardhan, GA, Liu, YY. Sphingolipids and expression regulation of genes in cancer. Prog Lipid Res 2011, 50:104–114.
Pan, D, Boon‐Unge, K, Govitrapong, P, Zhou, J. Emetine regulates the alternative splicing of caspase‐9 in tumor cells. Oncol Lett 2011, 2:1309–1312.
Gu, S, Zhao, Y, Guo, J, Xu, F, Fei, C, Zhang, X, Xiao, C, Chang, C, Li, X. High expression of APAF‐1 elevates erythroid apoptosis in iron overload myelodysplastic syndrome. Tumour Biol 2014, 35:2211–2218.
Jung, J, Kim, HY, Maeng, J, Kim, M, Shin, DH, Lee, K. Interaction of translationally controlled tumor protein with Apaf‐1 is involved in the development of chemoresistance in HeLa cells. BMC Cancer 2014, 14:165.
Poyurovsky, MV, Katz, C, Laptenko, O, Beckerman, R, Lokshin, M, Ahn, J, Byeon, IJ, Gabizon, R, Mattia, M, Zupnick, A, et al. The C terminus of p53 binds the N‐terminal domain of MDM2. Nat Struct Mol Biol 2010, 17:982–989.
Gu, D, Wang, S, Kuiatse, I, Wang, H, He, J, Dai, Y, Jones, RJ, Bjorklund, CC, Yang, J, Grant, S, et al. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild‐type and mutant p53 models of multiple myeloma, and acts synergistically with ABT‐737. PLoS One 2014, 9:e103015.
Marine, JC, Dyer, MA, Jochemsen, AG. MDMX: from bench to bedside. J Cell Sci 2007, 120:371–378.
Wade, M, Wang, YV, Wahl, GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010, 20:299–309.
Evans, SC, Viswanathan, M, Grier, JD, Narayana, M, El‐Naggar, AK, Lozano, G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 2001, 20:4041–4049.
Mermoud, JE, Cohen, PT, Lamond, AI. Ser/Thr‐specific protein phosphatases are required for both catalytic steps of pre‐mRNA splicing. Nucleic Acids Res 1992, 20:5263–5269.
Mermoud, JE, Cohen, PT, Lamond, AI. Regulation of mammalian spliceosome assembly by a protein phosphorylation mechanism. EMBO J 1994, 13:5679–5688.
Shi, Y, Reddy, B, Manley, JL. PP1/PP2A phosphatases are required for the second step of Pre‐mRNA splicing and target specific snRNP proteins. Mol Cell 2006, 23:819–829.
Iwanaga, N, Kamachi, M, Aratake, K, Izumi, Y, Ida, H, Tanaka, F, Tamai, M, Arima, K, Nakamura, H, Origuchi, T, et al. Regulation of alternative splicing of caspase‐2 through an intracellular signaling pathway in response to pro‐apoptotic stimuli. J Lab Clin Med 2005, 145:105–110.
Wang, JC. Cellular roles of DNA topoisomerases: amolecular perspective. Nat Rev Mol Cell Biol 2002, 3:430–440.
Labourier, E, Rossi, F, Gallouzi, IE, Allemand, E, Divita, G, Tazi, J. Interaction between the N‐terminal domain of human DNA topoisomerase I and the arginine‐serine domain of its substrate determines phosphorylation of SF2/ASF splicing factor. Nucleic Acids Res 1998, 26:2955–2962.
Malanga, M, Czubaty, A, Girstun, A, Staron, K, Althaus, FR. Poly(ADP‐ribose) binds to the splicing factor ASF/SF2 and regulates its phosphorylation by DNA topoisomerase I. J Biol Chem 2008, 283:19991–19998.
Coté, J, Dupuis, S, Jiang, Z, Wu, JY. Caspase‐2 pre‐mRNA alternative splicing: identification of an intronic element containing a decoy 3′ acceptor site. Proc Natl Acad Sci 2001, 98:938–943.
Fushimi, K, Ray, P, Kar, A, Wang, L, Sutherland, LC, Wu, JY. Up‐regulation of the proapoptotic caspase‐2 splicing isoform by a candidate tumor suppressor, RBM5. Proc Natl Acad Sci 2008, 105:15708–15713.
Solier, S, De Cian, MC, Bettaieb, A, Desoche, L, Solary, E, Corcos, L. PKC zeta controls DNA topoisomerase‐dependent human caspase‐2 pre‐mRNA splicing. FEBS Lett 2008, 582:372–378.
Schmitt, C, Miralinaghi, P, Mariano, M, Hartmann, RW, Engel, M. Hydroxybenzothiophene ketones are efficient pre‐mRNA splicing modulators due to dual inhibition of Dyrk1A and Clk1/4. ACS Med Chem Lett 2014, 5:963–967.
Naro, C, Sette, C. Phosphorylation‐mediated regulation of alternative splicing in cancer. Int J Cell Biol 2013, 2013:151839.
Kaida, D, Motoyoshi, H, Tashiro, E, Nojima, T, Hagiwara, M, Ishigami, K, Watanabe, H, Kitahara, T, Yoshida, T, Nakajima, H, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre‐mRNA. Nat Chem Biol 2007, 3:576–583.
Roybal, GA, Jurica, MS. Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation. Nucleic Acids Res 2010, 38:6664–6672.
Kotake, Y, Sagane, K, Owa, T, Mimori‐Kiyosue, Y, Shimizu, H, Uesugi, M, Ishihama, Y, Iwata, M, Mizui, Y. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 2007, 3:570–575.
O`Brien, K, Matlin, AJ, Lowell, AM, Moore, MJ. The biflavonoid isoginkgetin is a general inhibitor of Pre‐mRNA splicing. J Biol Chem 2008, 283:33147–33154.
Singh, RK, Cooper, TA. Pre‐mRNA splicing in disease and therapeutics. Trends Mol Med 2012, 18:472–482.
Bonnal, S, Vigevani, L, Valcárcel, J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 2012, 11:847–859.
Moore, MJ, Wang, Q, Kennedy, CJ, Silver, PA. An alternative splicing network links cell‐cycle control to apoptosis. Cell 2010, 142:625–636.
Castanotto, D, Stein, CA. Antisense oligonucleotides in cancer. Curr Opin Oncol 2014, 26:584–589.
Moreno, PM, Pêgo, AP. Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem 2014, 14:87.
Bauman, JA, Kole, R. Modulation of RNA splicing as a potential treatment for cancer. Bioeng Bugs 2011, 2:125–128.